Roquette Acquires Itacel

Article

Roquette has completed its previously announced acquisition of Itacel, an excipient division of Blanver.

On Sept. 1, 2017, Roquette, a French biopharmaceutical company specializing in plant-based excipients, completed the previously announced acquisition of Itacel. Itacel is an excipient division of Blanver, a Brazilian multinational company specializing in the development, manufacture, and commercialization of raw materials and drugs.

The acquisition is part of a series of investments made by Roquette to position itself globally, according to the company. Financial details of the closing are unpublicized.

Source: Roquette

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Recent Videos
Lee Cronin, founder and CEO of Chemify
Nicole Hunter, head of Global WMArchitect at Watson-Marlow Fluid Technology Solutions
Related Content
© 2025 MJH Life Sciences

All rights reserved.